NOL Index in Response to Pacemaker Stimulation
Launched by INSTITUTUL DE URGENŢĂ PENTRU BOLI CARDIOVASCULARE PROF.DR. C.C. ILIESCU · Nov 17, 2024
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to understand how heart pacing affects a special measurement called the Nociception Level Index (NOL Index), which helps assess pain levels during anesthesia. The NOL Index measures the balance between signals that indicate pain and those that help block pain. While we know how it responds to certain pain-relieving medications, researchers want to see how changes in heart rate from pacing influence this index.
If you're considering participating in this trial, you should be between the ages of 65 and 74 and have a stable heart rhythm before and after surgery. Participants need to give their consent and must not be undergoing emergency procedures or have a history of heart rhythm problems. During the trial, you can expect to be monitored closely to see how your heart pacing impacts the NOL Index. This research could help improve how we manage pain during surgeries in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Informed consent
- • Preoperative and postoperative sinus rhythm (50-80 bpm)
- • Norepinephrine support \< 100 ng/kg/min
- Exclusion Criteria:
- • Redo or emergent surgery
- • History of any cardiac arrhythmia
- • Any cardiocirculatory support other than norepinephrine
- • Perioperative treatment with beta-blockers, calcium-channel blockers or ivabradine
About Institutul De Urgenţă Pentru Boli Cardiovasculare Prof.Dr. C.C. Iliescu
The Institutul de Urgenţă pentru Boli Cardiovasculare Prof. Dr. C.C. Iliescu is a leading clinical research institution dedicated to advancing the understanding and treatment of cardiovascular diseases. Renowned for its commitment to innovative research and high-quality patient care, the institute conducts rigorous clinical trials aimed at developing new therapeutic strategies and improving clinical outcomes for patients with heart conditions. With a team of experienced professionals and state-of-the-art facilities, the institute plays a pivotal role in the cardiovascular research landscape, fostering collaboration and knowledge dissemination within the medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bucharest, , Romania
Patients applied
Trial Officials
Serban-Ion Bubenek-Turconi, Professor
Study Chair
CC Iliescu Cardiovascular Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported